[C:1]1([CH3:28])[CH:6]=[CH:5][C:4]([C:7]2[N:8]=[CH:9][N:10]([C:12]3[C:13]4[N:14]([CH:25]=[CH:26][N:27]=4)[CH:15]=[C:16]([C:18]4[CH:19]=[C:20]([NH2:24])[CH:21]=[CH:22][CH:23]=4)[N:17]=3)[CH:11]=2)=[CH:3][CH:2]=1.[N:29]([C:32]1[CH:37]=[CH:36][CH:35]=[CH:34][C:33]=1[CH3:38])=[C:30]=[O:31].CN(C=O)C>ClCCl>[C:33]1([CH3:38])[CH:34]=[CH:35][CH:36]=[CH:37][C:32]=1[NH:29][C:30]([NH:24][C:20]1[CH:21]=[CH:22][CH:23]=[C:18]([C:16]2[N:17]=[C:12]([N:10]3[CH:11]=[C:7]([C:4]4[CH:3]=[CH:2][C:1]([CH3:28])=[CH:6][CH:5]=4)[N:8]=[CH:9]3)[C:13]3[N:14]([CH:25]=[CH:26][N:27]=3)[CH:15]=2)[CH:19]=1)=[O:31]A solution of 3-[8-(4-p-tolyl-imidazol-1-yl)-imidazo[1,2-a]pyrazin-6-yl]-phenylamine (5) (50 mg), 1-isocyanato-2-methyl-benzene (18 mg), in dichloromethane (DCM) (3 ml) and DMF (0.5 ml) is stirred at room temperature for 16 hr. The mixture is concentrated in vacuo, the residue slurried with diethyl ether/methanol (20:1), and filtered to give 1-o-tolyl-3-{3-[8-(4-p-tolyl-imidazol-1-yl)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-urea (6) (40 mg) as a cream solid.